Trial Profile
PMS [post marketing surveillance] assessing the safety and efficacy of telmisartan in patients with mild to moderate essential hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2012
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 18 May 2012 Actual patient number chnaged from (34329) to (33247) as reported by ClinicalTrials.gov.
- 05 Mar 2010 Actual patient number (34329) added as reported by ClinicalTrials.gov.
- 05 Mar 2010 Status change from recruiting to completed as reported by CliniclaTrials.gov record.